Replies to post #201073 on Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

yeah - microbiome where it is at -- how to modulate for effect
Seres one such company... a Biotech Unicorn of sorts

http://www.fiercebiotech.com/biotech/seres-plots-ulcerative-colitis-trial-drive-after-posting-1b-data

re how B impacts the gut am assuming largely in a compensatory (+) way given the apparent major Defensin/Mucin deficiency in IBD, esp Crohn's ---- the academic research compiled by IPIX is rather compelling as to its potential.

"Defensin Therapeutics", per below, sounds almost as good as the "Brilacidin Platform" --- except we have a drug in multiple mid-stage trials, reality not concept.

https://www.defensintherapeutics.com/

[baytdr]

I suspect a supplemental probiotic may go a long way in insuring the re-population of desirable gut bacteria have great advantage.

[F1ash]

How do you get the antiinflammatory benefit without killing off gut bacteria since B also has major antibacterial action?

I’m not informed enough to know exactly where in the GI tract Brilacidin would be introduced (excreted) but the drug apparently is not metabolized and I don’t remember seeing any GI issues with the ABSSI trial.

“The majority of brilacidin (PMX-30063) was eliminated unchanged via fecal route and there was no indication of metabolism in liver or kidney.”

https://globenewswire.com/news-release/2012/09/11/490223/10004800/en/PolyMedix-Presents-New-Data-on-Its-Defensin-Mimetic-Antibiotics-at-52nd-Annual-ICAAC.html